Why Do Patients Need the Named Patient Program?

The gap between drug approval and availability across countries can be substantial. Consider:

Scenario 1: A lung cancer patient with a specific genetic mutation could benefit from an FDA-approved targeted therapy, but it is not yet approved by CDSCO in India. Without NPP, the patient’s only options are less effective standard chemotherapy or traveling abroad at prohibitive cost.

Scenario 2: A rare genetic disorder in a child has a internationally approved therapy by the EMA in Europe. This therapy could halt disease progression, but it is unavailable in India. NPP provides a legal pathway for the child’s physician to request this potentially life-saving treatment.

Scenario 3: An advanced cancer patient has exhausted all standard treatments. A novel immunotherapy approved by the FDA shows medically valuable option internationally but is years away from CDSCO approval. NPP enables the physician to formally request this final meaningful treatment option.

How the Named Patient Program Helps Patients Access Lifesaving Treatments

The NPP operates on fundamental principles protecting patients while facilitating legitimate access:

1. Unmet Medical Need Recognition: The NPP acknowledges that when patients have serious illness, no satisfactory approved alternative in India, exhausted standard treatments, and a potential internationally-approved solution, they deserve access to potentially lifesaving medicines.
2. Physician-Driven Medical Judgment: The treating physician—who knows the patient’s complete history and has expertise to weigh risks and benefits—determines suitability. The physician documents clinical rationale and risk-benefit analysis.
3. Regulatory Oversight: CDSCO carefully reviews each application, verifying the drug is approved internationally, the patient meets criteria for serious illness, no adequate alternatives exist in India, and safety monitoring is adequate.
4. Legal Importation Process:Once CDSCO grants Form 12B permission, the medicine can be legally imported. This is formal, documented, legal importation—not smuggling or black-market acquisition.
5. Supervised Medical Administration: The patient receives the medicine only under their physician’s direct supervision. The doctor monitors efficacy and safety, maintains records, and adjusts treatment as needed.

NPP has proven particularly valuable for:

• Rare Disease Patients: Those with rare genetic disorders or rare cancers often find no approved therapy in India. NPP enables access to internationally proven treatments.
• Advanced Cancer Patients: When cancer has progressed beyond standard options, newer targeted therapies or immunotherapies approved internationally may offer meaningful benefit.
• Orphan Disease Patients: Approximately 400 FDA-approved and 80 EMA-approved orphan drugs exist globally but are unavailable in India due to low commercial demand.
• Patients with Unmet Medical Needs: Patients whose specific disease characteristics mean existing approved medicines are unsuitable can access suitable international alternatives.

The Difference Between NPP and Illegal Drug Acquisition

Aspect	NPP (Legal)	Other Ways
Regulatory Approval	CDSCO formally approves via Form 12B	No regulatory oversight
Physician Involvement	Required with clinical documentation	Often absent
Drug Source	Legitimate international manufacturers	Unverified, potentially counterfeit sources
Quality Assurance	FDA/EMA-approved manufacturer	No quality assurance; risk of counterfeit products
Patient Safety Monitoring	Physician monitors and reports to CDSCO	No medical supervision
Legal Status	Completely legal and transparent	Illegal

The Role of Advocates Like MitoGENE

Organizations like MitoGENE facilitate the NPP process by:

• Educating patients and physicians about NPP and eligibility
• Facilitating patients to get 12 B import permit for personal use from CDSCO
• Connecting patients with legitimate international medicine sources
• Ensuring regulatory compliance
• Providing documentation support for NPP applications
• Coordinating logistics for legal importation and delivery

By working with MitoGENE, patients access expertise and connections necessary to navigate NPP successfully.

“Plz Note: All clinical decisions—including whether a therapy is suitable—are made solely by the treating physician and MitoGENE does not influence prescribing decisions or the medical judgment of physicians”

Conclusion

The Named Patient Program represents a balanced solution to a complex problem: the gap between medical innovation and regulatory approval. By providing a transparent, physician-driven, regulated pathway for patients to access internationally approved medicines when domestic options are exhausted, NPP acknowledges a fundamental principle—a patient’s access to potentially lifesaving medicine should not be limited solely by their country’s approval timeline when safer, regulated alternatives exist. For patients, NPP offers hope. For physicians, it enables their best medical judgment. For regulators, it balances innovation access with safety oversight. For families facing life-threatening illness, NPP can mean the difference between despair and possibility.

Disclaimer

MitoGENE facilitates patient-specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B. The products mentioned are not approved for commercial sale in India. Access is strictly for personal use under physician supervision. Information provided on this website is sourced from publicly available references, and MitoGENE is not responsible for its completeness or accuracy. MitoGENE does not promote or sell unapproved drugs.